Mitotane is the reference drug for the adrenocortical carcinoma treatment; its pharmacological activity seems to depend on drug transformation in two active metabolites: o,p'-DDE (dichlorodiphenylethene) and o,p'-DDA (dichlorodiphenylacetate). Mitotane and metabolites are lipophilic agents; thus, they tend to accumulate into adipose tissues (white and brown), which change their prevalence seasonally. Aim of the work was to evaluate mitotane and metabolites plasma levels variation over the year, in adrenocortical cancer patients treated with Lysodren(®) for at least 6 months
Introduction Mitotane is the only drug registered specifically for adrenocortical carcinoma. Finding...
Background: Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma. The ant...
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from the adrenal c...
Objective: Mitotane is the drug of choice in patients with adrenocortical carcinoma. The anti-neopla...
Mitotane (o,p'-DDD) acts mainly as an inhibitor of intramitochondrial pregnenolone and cortisol synt...
Mitotane (o,p'-DDD or (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl]ethane, DDD) is the drug of...
Eight patients with adrenocortical cancer were treated with low doses of mitotane (2-3 g daily) whil...
Background: Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)...
Toxicity of adjuvant mitotane treatment is poorly known; thus, our aim was to assess prospectively t...
Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical carcinoma. ...
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis. Mitotane, a der...
Background Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)....
Background Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)....
Introduction Mitotane is the only drug registered specifically for adrenocortical carcinoma. Finding...
Background: Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma. The ant...
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from the adrenal c...
Objective: Mitotane is the drug of choice in patients with adrenocortical carcinoma. The anti-neopla...
Mitotane (o,p'-DDD) acts mainly as an inhibitor of intramitochondrial pregnenolone and cortisol synt...
Mitotane (o,p'-DDD or (1,1-dichloro-2-[o-chlorophenyl]-2-[p-chlorophenyl]ethane, DDD) is the drug of...
Eight patients with adrenocortical cancer were treated with low doses of mitotane (2-3 g daily) whil...
Background: Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)...
Toxicity of adjuvant mitotane treatment is poorly known; thus, our aim was to assess prospectively t...
Mitotane is used as a post-operative adjuvant treatment for patients with adrenocortical carcinoma. ...
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy with a poor prognosis. Mitotane, a der...
Background Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)....
Background Mitotane is the only approved treatment for patients with adrenocortical carcinoma (ACC)....
Introduction Mitotane is the only drug registered specifically for adrenocortical carcinoma. Finding...
Background: Mitotane is the drug of choice in medical treatment of adrenocortical carcinoma. The ant...
Adrenocortical carcinoma (ACC) is a rare and aggressive endocrine tumour deriving from the adrenal c...